CRESCENT BIOPHARMA, INC.: 10-Q filed 2015-11-12

Name: CRESCENT BIOPHARMA, INC.: 10-Q filed 2015-11-12
Creator: CRESCENT BIOPHARMA, INC.

What CRESCENT BIOPHARMA, INC. reported in its quarterly report filed 2015-11-12 (fiscal Q3 2015): 30 published measures, 83 facts as tagged in accession 0001558370-15-002591.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-11-12
Fiscal period: fiscal Q3 2015
Accession: 0001558370-15-002591 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CRESCENT BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-09-30	55,741,823	USD
At 2014-12-31	57,263,973	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-09-30	7,036,825	USD
At 2014-12-31	6,460,545	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-09-30	48,704,998	USD
At 2014-12-31	50,803,428	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-09-30	53,759,839	USD
At 2014-12-31	55,198,923	USD
At 2014-09-30	61,362,103	USD
At 2013-12-31	2,310,603	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-7,168,071	USD	92
2015-01-01 to 2015-09-30	-3,887,795	USD	273
2014-07-01 to 2014-09-30	-6,617,577	USD	92
2014-01-01 to 2014-09-30	-3,727,707	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	265,367	USD	273
2014-01-01 to 2014-09-30	197,738	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	20,035,375	USD	273
2014-01-01 to 2014-09-30	15,027,004	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-09-30	-78,284,770	USD
At 2014-12-31	-74,396,975	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	19,025,623	shares	92
2015-01-01 to 2015-09-30	18,999,705	shares	273
2014-07-01 to 2014-09-30	18,893,834	shares	92
2014-01-01 to 2014-09-30	18,311,358	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	19,025,623	shares	92
2015-01-01 to 2015-09-30	18,999,705	shares	273
2014-07-01 to 2014-09-30	18,893,834	shares	92
2014-01-01 to 2014-09-30	18,311,358	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-0.38	USD/shares	92
2015-01-01 to 2015-09-30	-0.2	USD/shares	273
2014-07-01 to 2014-09-30	-0.35	USD/shares	92
2014-01-01 to 2014-09-30	-0.2	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-0.38	USD/shares	92
2015-01-01 to 2015-09-30	-0.2	USD/shares	273
2014-07-01 to 2014-09-30	-0.35	USD/shares	92
2014-01-01 to 2014-09-30	-0.2	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	-76,758	USD	92
2014-01-01 to 2014-09-30	0	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-09-30	567,219	USD
At 2014-12-31	452,270	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-7,171,373	USD	92
2015-01-01 to 2015-09-30	-3,897,299	USD	273
2014-07-01 to 2014-09-30	-6,699,162	USD	92
2014-01-01 to 2014-09-30	-3,741,570	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-09-30	54,478,073	USD
At 2014-12-31	56,115,172	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-09-30	6,850,299	USD
At 2014-12-31	6,460,545	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-09-30	633,093	USD
At 2014-12-31	874,028	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	5,038,380	USD	92
2015-01-01 to 2015-09-30	18,088,994	USD	273
2014-07-01 to 2014-09-30	5,050,666	USD	92
2014-01-01 to 2014-09-30	14,290,083	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-09-30	19,037,133	shares
At 2014-12-31	18,939,838	shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2015-09-30	1,420,251	USD
At 2014-12-31	1,357,749	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2015-09-30	853,032	USD
At 2014-12-31	905,479	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-09-30	5,521,699	USD
At 2014-12-31	4,735,719	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2015-09-30	718,234	USD
At 2014-12-31	916,249	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-7,168,071	USD	92
2015-01-01 to 2015-09-30	-3,887,795	USD	273
2014-07-01 to 2014-09-30	-6,694,335	USD	92
2014-01-01 to 2014-09-30	-3,727,707	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	2,132,993	USD	92
2015-01-01 to 2015-09-30	5,843,680	USD	273
2014-07-01 to 2014-09-30	1,648,496	USD	92
2014-01-01 to 2014-09-30	4,478,491	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	51,882	USD	92
2015-01-01 to 2015-09-30	142,417	USD	273
2014-07-01 to 2014-09-30	40,789	USD	92
2014-01-01 to 2014-09-30	114,261	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	3,302	USD	92
2015-01-01 to 2015-09-30	9,504	USD	273
2014-07-01 to 2014-09-30	4,827	USD	92
2014-01-01 to 2014-09-30	13,863	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	57,248,219	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	-240,935	USD	273
2014-01-01 to 2014-09-30	-561,176	USD	273

Inspect the source

Entity: CRESCENT BIOPHARMA, INC. / CIK 0001253689
Captured: 2026-09-20T07:46:49.806Z
SEC response SHA-256: b4a6cd55809d9037713a6469afddaa482d358690abc0227f51b6714b6bda1dce

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001253689.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))